Category: Pharmaceuticals and Biotech

Royal Biologics Launches Amnio-Maxx™, an Extracellular Matrix Product Derived From Human Amniotic Placental Tissue
FEATURED
Press Release Feb 6, 2018
Royal Biologics Launches Amnio-Maxx™, an Extracellular Matrix Product Derived From Human Amniotic Placental Tissue

50% Commission Offering for Initial Distributors. Amnio-Maxx™ will be used to treat various conditions in orthopedics and sports medicine.
Royal Biologics Announces FDA Approval of the Maxx™ Concentration System.
Press Release Sep 8, 2021
Royal Biologics Announces FDA Approval of the Maxx™ Concentration System.
Royal Biologics Announces Partnership With Vilex Launching Its ALC Technology Into Lower Extremity Industry
Press Release Aug 17, 2021
Royal Biologics Announces Partnership With Vilex Launching Its ALC Technology Into Lower Extremity Industry
Press Release Sep 29, 2020
Royal Biologics Completes 100th Cyro Cord™ Case, Successfully Enrolls First Patient Into Diabetic Foot Ulcer Study
Press Release Sep 1, 2020
Royal Biologics Announces the Acquisition of FIBRINET

The acquisition of the FIBRINET system adds new novel technology to Royal Biologics' growing portfolio of Autologous Live Cell solutions